3-(carbomethoxy)-2-ethyl-1-(phenylmethyl)-5-methoxyindole | 184705-08-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 3-(carbomethoxy)-2-ethyl-1-(phenylmethyl)-5-methoxyindole
• 英文别名: methyl 1-benzyl-2-ethyl-5-methoxyindole-3-carboxylate；1-Benzyl-2-ethyl-5-methoxy-1H-indole-3-carboxylic acid methyl ester
• CAS: 184705-08-6
• 化学式: C₂₀H₂₁NO₃
• 分子量: 323.392
• InChiKey: BJUKQEUMUKZADP-UHFFFAOYSA-N

物化性质

• 沸点：
  508.4±50.0 °C(Predicted)
• 密度：
  1.12±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  24
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  40.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-(carbomethoxy)-2-ethyl-1-(phenylmethyl)-5-methoxyindole 在 lithium aluminium tetrahydride 、 三氟化硼乙醚 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 5.0h， 生成 3-(cyanomethyl)-2-ethyl-1-(phenylmethyl)-5-methoxyindole
  参考文献：
  名称：

  A Practical, Nenitzescu-Based Synthesis of LY311727, the First Potent and Selective s-PLA₂ Inhibitor

  摘要：

  DOI：

  10.1021/jo9614452
• 作为产物：
  描述：

  methyl 3-(benzylamino)pent-2-enoate 在 sodium hydroxide 、 四丁基溴化铵 作用下， 以 硝基甲烷 为溶剂， 反应 48.5h， 生成 3-(carbomethoxy)-2-ethyl-1-(phenylmethyl)-5-methoxyindole
  参考文献：
  名称：

  A Practical, Nenitzescu-Based Synthesis of LY311727, the First Potent and Selective s-PLA₂ Inhibitor

  摘要：

  DOI：

  10.1021/jo9614452

文献信息

• Controlling the rates of reductively-activated elimination from the (indol-3-yl)methyl position of indolequinones
  作者：Steven A. Everett、Matthew A. Naylor、Paola Barraja、Elizabeth Swann、Kantilal B. Patel、Michael R. L. Stratford、Anna R. Hudnott、Borivoj Vojnovic、Rosalind J. Locke、Peter Wardman、Christopher J. Moody

  DOI：10.1039/b009652k

  日期：——

  A series of substituted 3-(4-nitrophenyloxy)methylindole-4,7-diones (Q) were synthesised. The effects of substitution patterns on the indole core on rates of elimination of 4-nitrophenol as a model for drug release following fragmentation of a phenolic ether linker were studied. After reduction to either the radical anion (Q˙−) or hydroquinone (QH2) elimination of 4-nitrophenol occurred from the (indol-3-yl)methyl position. The half-lives of Q˙− radicals at [O2] ≈ 5 µmol dm−3, typical of tumour hypoxia, were t½ ≈ 0.3–1.8 ms, the higher values associated with higher reduction potentials. Half-lives for the autoxidation of the QH2 were markedly longer at the same oxygen concentration (t½ ≈ 8–102 min) and longer still in the presence of 4 µmol dm−3 superoxide dismutase (t½ ≈ 8–19 h). Although the indolequinones were able to eliminate 4-nitrophenol with high efficiency only Q˙− radicals of the 3-carbinyl substituted derivatives did so with sufficiently short half-lives (t½ ≈ 41–2 ms) to compete with electron transfer to oxygen and therefore have the potential to target the leaving group to hypoxic tissue. The hydroquinones are not sufficiently oxygen sensitive to prevent the elimination of 4-nitrophenol (t½ ≈ 1.5–3.5 s) even at oxygen concentrations expected in normal tissue. By incorporating electron rich substituents at the indolyl carbinyl position it is possible to control the rate of reductive fragmentation. This may prove an important factor in the design of an indolequinone-based bioreductive drug delivery system.

  合成了一系列取代的3-(4-硝基苯氧基)甲基吲哚-4,7-二酮（Q）。研究了取代模式对吲哚核心在4-硝基苯酚释放速率上的影响，作为药物释放的模型，药物释放是通过酚醚连接链的断裂发生的。在还原为自由基阴离子（Q˙−）或氢醌（QH2）后，4-硝基苯酚从（吲哚-3-基）甲基位置释放。Q˙−自由基在[O2] ≈ 5 µmol dm−3（典型的肿瘤缺氧环境）下的半衰期为t½ ≈ 0.3–1.8毫秒，较高的半衰期值与较高的还原电位相关。在相同的氧浓度下，QH2的自氧化半衰期明显更长（t½ ≈ 8–102分钟），在存在4 µmol dm−3超氧化物歧化酶的情况下更长（t½ ≈ 8–19小时）。尽管吲哚醌能够以高效率释放4-硝基苯酚，但仅有3-羧基取代的Q˙−自由基具有足够短的半衰期（t½ ≈ 41–2毫秒）以与氧的电子转移竞争，因此具有将离去基团靶向缺氧组织的潜力。即使在正常组织中预期的氧浓度下，氢醌的氧敏感性不足以阻止4-硝基苯酚的释放（t½ ≈ 1.5–3.5秒）。通过在吲哚基甲基位置引入富电子取代基，可以控制还原性碎裂的速率。这可能成为设计基于吲哚醌的生物还原药物递送系统的重要因素。
• [EN] N-BENZYLINDOLE-3-ACETIC ACID DERIVATIVES FOR USE IN THE TREATMENT OF DRUG RESISTAN CANCER<br/>[FR] DERIVES D'ACIDE ACETIQUE N-BENZYLINDOLE-3 POUVANT ETRE UTILISES DANS LE TRAITEMENT DE CANCERS PHARMACORESISTANTS
  申请人：UNIV DUBLIN CITY

  公开号：WO2002020478A1

  公开（公告）日：2002-03-14

  A family of compounds, N-Benzylindoel-3-acetic acid derivatives, are active as inhibitors of multiple drug resistance protein (MRP) while having low direct toxicity, low COX -1 inhibitory activity and, in some cases, having useful activities such as COX-1 inhibition. The agents are useful in combination with MRP substrate drugs in the treatment of, for example, drug resistant cancer or tumours likely to develop drug resistant cancers because they can be given at higher concentration while being less toxic and having less side effects than known MRP inhibitors. The agents may also be more beneficial in the treatment of diseases which are dependent on MRP-1 activity or where MRP-1 activity reduces the effectiveness of existing therapies.
• Synthesis of indomethacin analogues for evaluation as modulators of MRP activity
  作者：Anita R. Maguire、Stephen J. Plunkett、Sébastien Papot、Martin Clynes、Robert O'Connor、Samantha Touhey

  DOI：10.1016/s0968-0896(00)00292-3

  日期：2001.3

  Synthesis of a range of indomethacin analogues, required for investigation in combination toxicity assays, bearing both N-benzyl and N-benzoyl groups, is described. (C) 2001 Elsevier Science Ltd. All rights reserved.
• A Practical, Nenitzescu-Based Synthesis of LY311727, the First Potent and Selective s-PLA₂ Inhibitor
  作者：J. M. Pawlak、V. V. Khau、D. R. Hutchison、M. J. Martinelli

  DOI：10.1021/jo9614452

  日期：1996.1.1